Clinical and laboratory outcomes during the treatment of rheumatoid arthritis with methotrexate. by Cannon, Grant W. & Reading, J.C.
Clinical and Laboratory Outcomes during the Treatment 
of Rheumatoid Arthritis with Methotrexate
G. W . C A N N O N , J. C. R E A D IN G , J. R. W ARD, L . J. B L O N Q U IS T  
and L. B. C O L L E T T E
Division o f  Rheum atology, Departm ent o f  Internal Medicine, and the Departm ent o f  
Family and Community Medicine, University o f  Utah School o f  Medicine, Salt Lake City,
Utah, and M edical Service, VA M edical Center, Salt Lake City, Utah, U.S.A.
S c a n d  J  R h e u m a t o l o g y  1 9 : 2 8 5 - 2 9 4 , 1 9 9 0
Cannon GW, Reading JC, Ward JR, Blonquist LJ, Collette LB. Clinical and laboratory 
outcomes during the treatment of rheumatoid arthritis with methotrexate. Scand J 
Rheumatology 1990; 19: 285-294, 1990.
Ten clinical and three laboratory outcomes were evaluated in 86 patients completing a 
double-blind placebo-controlled trial of methotrexate in rheumatoid arthritis. The improve­
ment in all measured outcomes was statistically significantly better in patients receiving 
methotrexate than in patients receiving placebo. The correlations of the changes in 
outcome measures were calculated to determine if improvement in one parameter was 
associated with improvement in other clinical parameters. Associations between different 
clinical outcomes were often statistically significant. Associations between laboratory 
outcomes were also often statistically significant. However, the association between 
clinical outcomes and laboratory outcomes was generally poor.
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IN T R O D U C T IO N
M ethotrexate is an e ffectiv e  treatm ent for rheum atoid arthritis (RA) (1 -4 ). During treat­
m ent w ith m eth otrexate, there is im provem ent o f  other clin ical (1 -6 ) and laboratory (1-7 )  
m easures o f  d isea se  activ ity . Im provem ent in laboratory abnorm alities has been  im plied to 
correlate w ith  the clin ica l benefit o f  anti-rheum atic drug therapy. D ixon  et al. have 
su ggested  that correla tion s o f  im provem ent in c lin ica l and laboratory param eters may be 
useful for a sse ss in g  a drug’s anti-rheum atic activ ity  (8 -1 0 ), and may identify agents w ith  
potential 'd isea se  m odifying' qualities (8). S om e o f  th ese  observations may have been  
based on sta tistica l evaluations w hich  w ere not valid. It is critical to determ ine if changes  
in laboratory param eters correlate sign ificantly  w ith  ch an ges in clin ical param eters. Such  
an analysis cou ld  determ ine to w hat ex ten t ch an ges in laboratory abnorm alities can be 
exp ected  to correlate w ith  clin ica l o u tco m es.
T o address th ese  issu es , we evaluated the correlation  o f  changes in clin ical and laborato­
ry ou tcom es in 86 patients w h o  com p leted  a double-blind p laceb o-con trolled  trial o f  
m ethotrexate in R A . T hree issu es w ere con sid ered , 1) W ere the changes in clin ical and 
laboratory o u tco m es d ifferent in patients receiv in g  m ethotrexate and patients receiv in g  
placebo? 2) Is the correlation  b etw een  c lin ica l o u tco m es and laboratory o u tco m es in 
individual patients sta tistica lly  significant? 3) W hat is the frequency o f  ‘im portant’ im ­
provem ent occurring in a laboratory ou tcom e w ithout ‘im portant’ im provem ent occurring  
in a clin ical variable, and freq u en cy  o f  ‘im portant’ im provem ent occurring in a clin ical 
variable w ithout an ‘im portant’ im provem ent occurring in a laboratory ou tcom e?
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M E T H O D S
Patient selection
Eighty-six patients completing the 18-week treatment course o f the trial o f low-dose pulse methotrex­
ate versus placebo in RA directed by the Cooperative Systematic Study of Rheumatic Diseases were 
evaluated. This number is lower than the 110 patients reported in the clinical report of this trial, due to 
loss of 24 serum samples in transit to the central laboratory for analysis of RF and CRP. The details of 
patient selection for this trial are already described (1). In brief, all patients had definite or classic RA 
by American Rheumatism Association criteria (11), at least six swollen joints and at least two of the 
following: 1) nine or more tender joints, 2) forty-five or greater minutes of morning stiffness, and 3) 
Westergren ESR of 28 mm/h or greater.
Drug therapy
Patients were maintained on a stable dose of aspirin or a non-steroidal anti-inflammatory agent with or 
without a stable dose of prednisone up to 10 mg per day throughout the study. On entry into the study, 
patients were randomized to receive either methotrexate 2.5 mg tablets or identical placebo tablets. 
The study medication was administered as three oral doses at 12-h intervals each week. After 6 
weeks, if judged that there had been no clinical response and no serious toxicity had occurred, the 
dose of medication could be doubled to two tablets at a 12-h interval each week. The trial was 
terminated after 18 weeks of treatment. Each outcome measurement was classified as either a clinical 
or laboratory parameter (Table I).
Clinical evaluation
Ten clinical measures of disease active were recorded at the beginning and the end of the trial (Table 
I). Physicians assessed patients determine the tenderness of 60 diarthriodal joints graded on a scale of
Table I. C h a n g e a in o u t c o m e  m e a s u r e m e n t s  in m e t h o t r e x a t e  (M T X )  a n d  p l a c e b o  g r o u p s  
du r in g  18 w e e k s  o f  o b s e r v a t i o n  





1. Clinical variables 
(a) Subjective
(1) Joint tenderness count 10.4 ±  12.5 2.7±9.8 <0.001
(2) Joint tenderness score 20.5±23.8 8.1 ±23.2 0.006
(3) Morning stiffness (minutes) 170±336 14±314 0.007
(b) Objective
(1) Joint swelling count 6.2±7.7 — 1.5±8.6 <0.001
(2) Joint swelling score 12.5 ±  13.5 —0.4±  17.7 <0.001
(3) Grip strength (mm/Hg) — 32.0±34.0 0.4±21.4 <0.001
(4) PIP circumference (mm) 0.8±2.5 —0.8±2.4 <0.004
(5) Walking time (minutes) 3.1 ±5.3 2.5±7.4 0.046
(c) Global assessment
(1) Patient 0.8±1.0 0.3 ±1.1 0.018
(2) Physician 0.9±0.9 0.2±1.0 <0.001
2. Laboratory variables 
(a) Rheumatoid factor (RF)
(1) Latex agglutination* 1.5±1.4 —0.2±  1.1 <0.001
(2) FI AX (I.U./ml) 21.7±35.8 —24.0±68.1 <0.001
(b) C-reactive protein (CRP)
(1) Nephelometry (mg/di) 2.4±2.5 —0.3±2.0 <0.001
(2) FIAX (mg/dl) 3.1 ±3.4 -1 .0 ± 6 .6 <0.001
(c) Westergren ESR (mm/h) 20±21 —2±20 <0.001
“ Difference is value at entry minus the value at completion of the 18-week trial. 
b See methods section for calculation of change in RF titer.
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0 = none, 1 = positive respone on questioning, 2 = spontaneous response elicited, and 3 = 
withdrawal by the patient on examination. Joint swelling was determined for 58 diarthrodial joints 
graded as 0 = none, 1 = detectable synovial thickening without loss of distinctness of bony contours,
2 = loss of distinctiveness of bony contours and 3 = bulging synovial proliferation with cystic 
characteristics. The joint tenderness count (JTC) and joint swelling count (JSC) were the sum of the 
number of tender or swollen joints respectively. The joint tenderness score (JTS) and joint swelling 
score (JSS) were the sum of the scores of all tender or swollen joints respectively. Patient global 
disease assessment (PTGA) and physician global disease assessment (PHGA) were judged at the 
beginning and end of the study using the following scale: 1 = asymptomatic, 2 = mild, 3 = moderate, 
4 = severe, 5 = very severe. Duration of morning stiffness (MS), grip strength (GS), proximal 
interphalangeal joint circumference (PIP), and 50-foot walk time (WT) were measured by standard 
methods (1).
Laboratory evaluation
RF was measured in titer by a charcoal agglutination (Macro-Vue® card test, Becton Dickenson, 
Baltimore, Md) and in international units per milliliter (I.U./ml) by a quantitative solid-phase fluores­
cence immunoassay (FIA) using the FIAX® system (M.A. Bioproducts, Walkersville, Md) as pre­
viously described (12, 13). By measuring RF with two methods, the standard methodology using a 
non-continuous scale (titer by charcoal agglutination) used in most laboratories can be compared with 
a method using a continuous scale (I.U./ml by FIA) which may be more sensitive in detecting changes 
in RF. CRP was measured in mg/dl by a FIA (FIAX® system, M.A. Bioproducts, Walkersville, Md) 
and nephelometric methods (Beckman immunochemistry system, Brea, Calif.). All RF and CRP 
assays were done at the laboratory of the Division of Rheumatology, University of Utah. Westergren 
ESR was measured by the standard method at each of the nine participating clinics.
Determination o f  ‘im por tan t’ improvement
‘Important’ improvement for a clinical variable required a reduction of 50% or more in the JTC or 
JSC (1). ‘Important’ improvement in a laboratory variable was only determined if the baseline value 
was elevated above the normal range (RF (titer) >  1:40, RF >15 I.U./ml, CRP >0.8  mg/dl, or ESR 
>20 mm/h). ‘Important’ improvement for a laboratory variable required that there by a reduction of 
the level to 50% of baseline or to within the normal range. If ‘important’ improvement was not 
achieved, the status of changes in clinical and laboratory variables was further defined as either some 
improvement or no improvement/worsening. A classification of some improvement required improve­
ment from baseline which was not sufficient to achieve ‘important’ improveme■ . o improve­
ment/worsening was defined as either no change in the variable from baseline or a del n ation of the 
tested parameter.
Statistics
The differences in all clinical parameters, CRP, and ESR were calculated as the simple difference of 
the initial minus the final values. The differences in RF were calculated as the simple difference of the 
initial and final value in I.U./ml measured by the FIA method and as the change in the number of 
twofold dilution titers by the charcoal agglutination. (Examples: if an initial RF titer was 1:80 and 
final titer was 1:20 this was recorded as a 2 titer change (reduction) of RF titer. If an initial RF titer 
was 1: 160 and final titer was 1:640 this would be recorded as a - 2  titer change (increase) in RF titer.)
Due to the non-normal distribution of many of the response variables, changes in clinical and 
laboratory parameters for methotrexate- and placebo-treated patients were compared by Mann- 
Whitney tests. Correlations were compared by Spearman’s correlation. Comparisons of ‘important’ 
improvement were performed by %2—either 3 x 2  or 2 x 2  as noted on tables. Alpha less than 0.05 was 
considered statistically significant.
To compare our results with the previous work of Dixon (8, 10), Pearson correlation coefficients of 
mean ESR and each of four clinical variables (mean JTC, mean JTS, mean JSC, and mean JSS) were 
calculated at each of the four clinic visits (entry, 6 weeks, 12 weeks, and 18 weeks) for each of the two 
treatment groups. This yielded a total of 32 (two treatment, four variables, four visits) coefficients. 
ESR was the sole laboratory test used, since it was the only one measured on intermediate study 
visits.
R E SU L T S
C h a n g e s  in c l in ic a l  a n d  l a b o r a t o r y  o u t c o m e  m e a s u r e m e n t
A s previously  reported  (1), there w as im provem ent in all clin ical and laboratory m easures  
o f  RA d isea se  activ ity  during treatm ent w ith m ethotrexate. T h ese  ch an ges in patient
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receiving m eth otrexate  w ere sta tistica lly  d ifferent than ch an ges in patients receiv ing  
placebo (Table I).
C o m p a r i s o n  o f  a s s a y  m e t h o d s  o f  R F  a n d  C R P
The change in R F titer correlated  sign ificantly  w ith the change in R F (I.U ./m l) by F IA  
(r= 0 .4 0 7 , p = 0 .007 , n = 43 in m eth otrexate-treated  patients; and r = 0 .5 4 2 , p < 0 .0 0 1 , n = 43 
for p lacebo-treated  patien ts). T h e ch an ges in CRP levels m easured by F IA  and n ep h elo ­
m etric m ethods correlated  sign ificantly  (r = 0 .7 8 2 , p < 0 .0 0 1 , n = 43 for m ethotrexate-treated  
patients, and r = 0 .7 4 1 , p < 0 .0 0 1 , n = 43 for p lacebo-treated  patients). T he su b seq u en t  
an alyses using R F by F IA  and la tex  agglutination  produced sim ilar resu lts. T hus on ly  the 
FIA  results are reported  hereafter w ith the data on  R F by latex  agglutination available on  
request. S im ilarly , m easu rem en t o f  CRP is su b seq u en tly  reported for F IA  o n ly , w ith  
results sim ilar to th ose  obta ined  w ith  nep h elom etry .
A s s o c i a t i o n s  o f  o u t c o m e  v a r ia b le s
Spearm an correlation  c o e ffic ien ts  and sign ifiance va lues for the a sso c ia tion s o f  o u tcom e  
m easures are listed  in T able II. In this tab le, the Spearm an correlation  co effic ien ts  are 
presented  below  the d iagonal and the p -va lu e for the correlation  is presented  above the
T able II. A s s o c a t i o n  o f  a ll  c h a n g e s  o f  c l in ic a l  p a r a m e t e r s
JTC JTS MS JSC JSS GS PIP WT PTGA PHGA RF CRP ESR
M TX patients (n = 4 3 ) 
JTC -  .001 .078 .012 .031 .188 .015 .189 .016 .001 .617 .265 .170
JTS .81 - .058 .081 .004 .116 .024 .088 .004 .001 .622 .319 .031
MS .27 .29 - .048 .026 .469 .003 .060 .014 .257 .760 .522 .114
JSC .38 .27 .30 - .001 .033 .073 .022 .038 .042 .664 .034 .354
JSS .33 .43 .34 .82 - .044 .050 .013 .010 .008 .489 .100 .194
GS .21 .25 .11 .33 .31 - .066 .028 .124 .023 .458 .203 .446
PIP .37 .35 .44 .28 .30 .29 - .002 .096 .416 .337 .014 .007
WT .22 .28 .31 .38 .40 .37 .49 - .210 .051 .121 .008 .001
PTGA .36 .43 .37 .38 .39 .29 .26 .21 - .001 .580 .927 .285
PHGA .51 .62 .18 .31 .40 .35 .13 .32 .56 - .179 .115 .503
RF .08 .08 .05 .07 .11 .12 .15 .26 .09 .21 - .034 .040
CRP .17 .16 .10 .32 .25 .20 .38 .43 .01 .24 .32 -  , .001
ESR .22 .33 .25 .15 .20 .12 .41 .54 .17 .11 .32 .56 -
Placebo pa tien ts  (n =  
JTC -  .001
43)
.045 .001 .001 .002 .130 .161 .067 .001 .414 .082 .589
JTS .88 - .146 .001 .001 .002 .081 .021 .006 .001 .518 .108 .683
MS .31 .23 - .037 .262 .039 .065 .077 .064 .123 .878 .163 .826
JSC .67 .57 .32 - .001 .066 .031 .584 .004 .001 .792 .007 .933
JSS .75 .74 .18 .79 - .007 .021 .020 .005 .001 .448 .032 .516
GS .47 .48 .33 .29 .42 - .024 .060 .644 .040 .156 .311 .661
PIP .24 .28 .29 .34 .36 .36 - .006 .010 .214 .403 .036 .335
WT .24 .39 .30 .10 .39 .34 .47 - .092 .106 .513 .611 .169
PTGA .28 .41 .29 .43 .42 .08 .40 .28 - .001 .549 .056 .463
PHGA .58 .63 .24 .64 .60 .33 .20 .28 .61 - .987 .051 .496
RF .13 .10 .02 .04 .12 .23 .13 .11 .09 .003 - .189 .007
CRP .27 .25 .22 .41 .33 .16 .33 .09 .29 .30 .20 - .010
ESR .09 .06 .03 .01 .10 .07 .15 .24 .12 .11 .41 .39 -
/•-value is below the diagonal (Spearman correlation coefficient), 
p-value is above the diagonal.
Change in Swelling Count vs. ESR
o M ethotrexate Patients i °
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Fig. 1. Changes in joint swelling count and change in Westergren ESR. For methotrexate patients 
(/j=43, r=0.15, p=0.354). For placebo patients ( n = 43, r=0.01, p = 0.933).
diagonal. T he num ber o f  sta tistica lly  sign ificant tests  w as com pared in three areas for each  
group, the correlation  o f  clin ical variables w ith  clin ical variables (45 tests), the correlation  
o f laboratory variables w ith  laboratory variables (3 tests), and the correlation  o f  clin ical 
variables w ith  laboratory variables (30 tests).
T h ese evalutions show  that there w as a statistica lly  significant a sso c ia tio n  (p < 0 .0 5 )  
betw een  m any variables for both patients receiv in g  p lacebo or m eth otrexate. W hen the 
m ethotrexate patients w ere evaluated , 28 o f  the 45 (62% ) correlations tests  betw een  
clinical variables ach ieved  statistical s ign ifican ce (/?=£0.05) and all three correlations  
betw een  laboratory variables show ed statistica l sign ificance. In contrast, on ly  six  o f  the 30 
(20% ) correlations betw een  clin ical and laboratory variables show ed statistica l sign ifi­
cance.
W hen the p laceb o  patients w ere evaluated , 29 o f  the 45 (64% ) correlations tests  betw een  
clinical variables ach ieved  sta tistica l s ign ifican ce and two o f  the three correlations b e­
tw een laboratory variables show ed statistica l s ign ificance. In contrast on ly  three o f  the 30 
(10% ) correlations b etw een  clin ical and laboratory variables show ed statistical sign ifiance.
Table III. P e a r s o n  c o r r e la t io n  o f  m e a n  W e s te r g r e n  E S R  w i th  m e a n  c l in ic a l  v a r ia b le  





Joint tenderness count 0.95 <0.0001 -0 .4 0.6
Joint tenderness score 0.97 <0.0001 0.2 0.6
Joint swelling count 0.91 <0.0001 -0 .4 0.6
Joint swelling score 0.96 <0.0001 0.4 0.6
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Joint Swelling Count vs. ESR
Dixon M ethod
Westergren ESR (mm/hour)
Fig. 2. Mean joint swelling count and mean Westergren ESR for patients receiving methotrexate 
(r=0.9I, p<0.0001) and placebo (/-=0.40, p = 0.60) at 0, 6, 12, and 18 weeks. Calculation as described 
by Dixon et al. (10).
A s an exam p le , the a sso c ia tio n  o f  the ch an ge in JSC and W estergren E SR  are show n in 
Fig. 1. A lthough the sta tistica l an a lysis  sh ow  significant correlations for all patients  
( r = 0.28, /? = 0 .004), the correla tion s for m ethotrexate patients (/— 0.15 , p = 0 .3 5 4 )  and 
placebo patien ts (r = 0 .0 1 , /j= 0 .9 3 3 )  w ere no statistica lly  significant. T he w id e scatter o f  
these data are appreciated  by this v isu al p resentation . T h ese  data are representative o f  the 
poor correlation  b etw een  clin ical and laboratory data w hich had a large degree o f  scatter  
and lacked sta tistica lly  sign ificant correlation .
A s s o c ia t io n s  o f  o u t c o m e  m e a s u r e  b y  m e t h o d s  p r e v io u s ly  r e p o r t e d
U sing the statistical evaluation  p rop osed  by D ix o n  et a l., we a lso  determ ined the correla­
tion o f  m ean JTC, JT S, JSC , and JSS w ith W estergren  E SR  (10). U sin g  this m eth od , there  
was a strong correlation  b etw een  the m ean JTC, JT S, JSC, JSS with m ean E SR  in patients 
receiving m ethotrexate (r = 0 .9 1 -0 .9 7 , /j< 0 .0 0 0 1 );  how ever there w as no sign ificant corre­
lation in patients receiv in g  p laceb o  (/— - 0 . 4 -0 .4 , p > 0.60) (Table III, F ig. 2).
E v a lu a t io n  o f  th e  ‘i m p o r t a n t ’ i m p r o v e m e n t  in o u t c o m e s  o f  t r e a tm e n t  g r o u p s  
The num ber o f  patients ach iev ing  ‘im portant’ im provem ent in clin ical and laboratory  
param eters w ere com pared in patien ts receiv in g  m ethotrexate and patients receiv in g  
placebo. A s an exam p le , a com p arison  o f  ‘im portant’ im provem ent in JSS is com pared  
with ‘im portant’ im provem ent in R F , C R P , and E SR  (Table IV ). In th ese evalu ation s, the 
distribution o f  patients ach ieving ‘im portant’ im provem ent in clin ical JTS and JSS  w as not 
associa ted  with a greater lik elih ood  o f  ‘im portant’ im provem ent in laboratory param eters. 
For exam p le , 37 o f  40 patients receiv in g  m ethotrexate exp erien ced  either ‘im portant’ 
im provem ent or som e im provem ent in R F during the study and 39 o f  40 patients ex p er i­
Scand J Rheum atology 19 M ethotrexate treatm ent o f  R A  2 9 1
enced either ‘im portant’ im provem ent or som e im provem ent in JSC during the study. 
H ow ever, patients w ith ‘im portant’ im provem ent in R F w ere no m ore likely  to ex p erien ce  
‘im portant’ im provem ent in JTC, than the patient w ho did not exp erien ce  an ‘im portant’ 
im provem ent in R F. A  sim ilar pattern w as seen  in com parison  o f  ‘im portant’ im provem ent 
in JTC with R F , CRP and E SR  (data available on request).
D IS C U S S IO N
Our data again dem onstrate an im provem ent in clin ical and laboratory m easu res o f  R A  
d isease activ ity  during treatm ent o f  patien ts w ith m eth otrexate. H ow ever, this analysis  
also show ed that an im provem ent in on e m easure o f  R A  is o ften  poorly  a sso c ia ted  with  
im provem ent in other o u tcom e param eters. T he lack o f  a ssoc ia tion  is particularly true in 
com paring laboratory and clin ica l param eters.
Table IV . ‘I m p o r t a n t ’ im p r o v e m e n t  in j o i n t  s w e l l in g  c o u n t  c o m p a r e d  w i th  ‘i m p o r t a n t ’ 
im p r o v e m e n t  in r h e u m a to id  f a c t o r ,  C - r e a c t i v e  p r o t e in ,  a n d  W e s te r g r e n  e r y t h r o c y t e  s e d i ­
m e n ta t io n  ra te  (E S R )





No change, or 
worsening
R heum ato id  fa c to r  
Methotrexate patients (n = 40)“'*
Important improvement 7 14 0
Some improvement 6 9 1
No change or worsening 0 3 0
Placebo patients (n = 40)
Important improvement 0 0 0
Some improvement 0 12 3
No change or worsening 1 20 4
C-reactive protein  
Methotrexate patients (n =  35)“'*
Important improvement 11 11 1
Some improvement 0 7 0 '
No change or worsening 2 3 0
Placebo patients (n=38)“iC
Important improvement 0 4 1
Some improvement 3 15 1
No change or worsening 0 10 4
ESR (m m lh )
Methotrexate patients (/? = 30)“,c
Important improvement 4 8 2
Some improvement 8 3 3
No change of worsening 2 0 0
Placebo patients (« = 33)",c
Important improvement 0 1 1
Some improvement 2 4 7
No change or worsening 1 5 12
a n< 86 because only patients with potential for important improvement were included (see Methods). 
b 2x2  y2-table.
The possib ility  o f  correlating clin ica l and laboratory ou tcom es to evaluate anti-rheum at­
ic drug ‘c la ss ifica tio n ’ is an in teresting p ostu la te . A lthough it is not d ifficult to determ ine if  
agents can be categorized  as co rtico stero id s or non-steroidal anti-inflam m atory drugs on 
chem ical properties, the c la ssifica tion  o f  slow -acting  anti-rheum atic drugs (S A A R D ) is 
m ore difficult. T h ese  a g en ts’ titles, such  as d isea se  m odifying, rem ission  inducing, and 
slow  acting, have generally  reflected  the attributes su sp ected , though not alw ays proven, 
for these agents. A lthough this group o f  drugs certain ly  represents a h eterogen eou s  
co llection  o f  agen ts, for the prupose o f  this d iscu ssio n , S A A R D s are defined  as anti­
rheum atic drugs w ith a delay o f  at least several w eek s betw een  initiating the drug and the 
initial on set o f  action . S A A R D s may be d isea se  m odifying, but this determ ination  m ust be 
proved by long-term  follow -up  o f  clin ical fea tu res, such as erosive changes on radiograph­
ic and developm ent o f  d eform ities, rather than b ioch em ica l changes.
A lthough several m easures o f  d isea se  activ ity  have been correlated in patients at a 
single evaluation  (14 -20 ), few stu d ies have correlated  ch an ges in th ese param eters (21 -26 ). 
C orticosteroids are know n to sign ificantly  reduce E S R  and C -reactive protein levels  (25), 
but they are not con sid ered  S A A R D  or d isease-m od ify in g  agents. N o  change in E S R  and 
CRP w as reported in patients receiv in g  non-steroidal anti-inflam m atory drugs in som e  
studies (20, 24, 25). A lthough there w as som e d ecrease  E SR  reported by M cG uire in 
patients receiv in g  in d om eth acin , there w as no correlation  with changes in E S R  and pain 
scores (26). ,
P rospective evaluation o f  the relationship  b etw een  changes in CRP and ch an ges in 
clinical m easures in groups o f  patien ts receiv in g  various S A A R D s have co n clu d ed  both  
that correlation co effic ien ts  b etw een  the tests  at intervals rarely attained sta tistica l sign ifi­
cance (21), and serial m easu rem en ts o f  CRP and E SR  provide a reliable m ean s o f  
discrim inating b etw een  drugs that provide sym ptom atic  relief on ly  and th ose  w ith  a m ore  
profound effect in rheum atoid arthritis (22). In a p rospective evaluation o f  patients  
receiving gold , D -p en icillam in e or h yd roxych loroq u in e there w as significant im provem ent 
in clin ical arthritis sco re , E S R , and R F (23). T he change in jo in t score correlated  w ith  E SR  
and IgG R F in a statistica lly  sign ificant relationship; how ever, there w as no sta tistica lly  
significant correlation  w ith change in IgM  R F. In a fo llow -up o f  this stu d y , correlation s o f  
change in IgM  R F with articular index  w ere sta tistica lly  significant in patients receiv in g  
gold (r = 0 .7 1 , p < 0 .0 1 ) ,  but not in p atien ts receiv in g  D -pen icillam ine (r = 0 .3 2 , p = N .S . )  or 
non-steroidal anti-inflam m atory drugs (r = 0 .2 5 , p = N .S .)  (24). A  correlation  o f  CRP and 
E SR  is previously  reported  (15); how ever, th is study on ly  evaluated a single se t o f  values  
and did not correlate ch an ges in E SR  or ch an ges in CRP with the initiation o f  therapy. T he  
search for laboratory m easures w hich  can  be used  to predict clin ical o u tco m es has b een  a 
difficult p rocess and produced little ev id en ce  that laboratory param eters can predict 
clinical ou tcom es.
This an a lysis has been  generated  at least in part in resp on se  to reports by D ix o n  et a l., 
im plying that the b ioch em ica l and clin ica l changes in R A  correlated  very c lo se ly  in 
patients receiv in g  S A A R D s (8 -1 0 ). In their previous w ork, D ixon  et al. su ggested  that a 
reduction in acu te-p h ase reactants w as a sso c ia ted  w ith a S A A R D  effec t, w h ile  no sign ifi­
cant changes w ere seen  w ith N S A ID s  (8 -1 0 ). T he major error in the reported statistica l 
analysis was the use o f  m ean data and repeated  m easures on the sam e patients to ca lcu la te  
the correlation co effic ien ts . It is im proper to perform  a correlation  using repeated  m ean  
data on the sam e su b jects. If serial m easurem ents are to be evaluated , they m ust be 
evaluated by statistica l tests  design ed  for this p u rp ose, such as m ultifactor repeated  
m easure an a lyses.
T o dem onstrate this problem , an a ly ses  o f  clin ical and laboratory param eters calcu lated  
by these d ifferent m ethods w ere com pared . JSC and E SR  w ere presented as an exam p le .
The m ethod describ ed  by D ix o n  et al. g ives a strong and statistica lly  sign ificant correlation
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( r = 0 .91 , /7< 0 .0001) in patients rece iv in g  m eth otrexate and no sta tistica lly  sign ificant 
correlation { r = —0 .4 0 , p = 0.60) in patien ts receiv in g  p lacebo (Table III, Fig. 2). H ow ever, 
the correlation  o f  ch an ges in E SR  b etw een  initial and final v isits and ch an ges in jo in t  
sw elling over the sam e tim e period w as not sta tistica lly  significant for patients receiv in g  
m ethotrexate (/-=0 .15 , p = 0 .3 5 4 , T able II, Fig. 1) and for patients receiv in g  p laceb o  
( r = 0 . 0 l , /7 = 0 .9 3 3 , T able III, F ig. 1). N o r  did com parison  o f  ‘im portant’ im provem ent in 
these param eters su ggest any a sso c ia tio n . B y  using m ean data at m ultiple tim es, the 
analysis by D ixon  et al. e ssen tia lly  com p ares the rate o f  change o f  the ou tcom e variables in 
the study population . A  high degree o f  sta tistica l correlation  w ould be achieved if  there  
were a relatively con stan t change in both  param eters w ithout any requirem ent that the 
changes in individual patients be proportionate. That is to say, if  the m ean E SR  decreased  
in patients receiv in g  m eth otrexate  and the JSC im proved, there is no assu ran ce, in the 
m ethods used  by D ix o n  et a l., to show  that the change in E SR  and jo in t sw elling  is 
correlated in individual p atien ts. Our an a lysis o f  changes in m ultiple laboratory and 
clinical param eters sh ow ed , in fact, that although there are frequently sign ificant ch an ges  
in clin ical and laboratory data from  b a se lin e , th ese  changes correlate poorly  in individual 
patients. T he lack o f  correlation  is m ost prom inent in the com parison  o f  c lin ica l and 
laboratory param eters. T h u s, the role o f  m easuring acute-phase reactants as a m ethod for 
detecting S A A R D  activ ity  is p resen tly  unclear.
To evaluate the p ossib ility  that large ch an ges in d isease  activ ity  m easu rem en ts o f  
clinical and laboratory o u tco m es w ould be m ore likely  to correlate, an an a lysis o f  ‘im por­
tant’ im provem ent in clin ica l and laboratory param eters w as also perform ed. Som e  
im provem ent or ‘im portant’ im provem ent occurred  in clin ical and laboratory param eters 
in m ost patients receiv in g  m eth otrexate; how ever, there w as no statistica lly  sign ificant 
association  o f  ‘im portant’ im provem ent in th ese  tw o param eters. A lthough few er patients  
receiving p laceb o  had ‘im portant’ im provem ent o f  clin ical and laboratory o u tco m es, there  
w as again no correlation  o f  ‘im portant’ im provem ent in clin ical and laboratory param eters  
in th ese patients.
A lthough results from  large pop u lation s are required to docum ent drug e ffica cy , th ese  
data raise the qu estion  o f  w hich  param eters a physician  should  fo llow  w h en  evaluating an 
individual patient. A s can be seen  from  our an a lysis , patients w ill o ften  exp er ien ce  
im provem ent in clin ica l and laboratory va lu es during treatm ent w ith m ethotrexate; h ow ev­
er, the correlation  o f  th ese  ch an ges is poor. It is a lso  quite clear that an im provem ent in 
one param eter, or perhaps m ore accu rately  the degree o f  im provem ent in on e param eter, 
will not predict c lin ica l resp on se  in other param eters. It is our practice to b ase the d ec is io n  
o f w hether an anti-rheum atic agent shou ld  be con tin u ed  on the clin ical ou tco m e, and not to  
rely on ch an ges in laboratory param eters in decid ing  to change m ed ication s.
In sum m ary, w e w ere able to dem on strate im provem ent in clin ical and laboratory  
ou tcom es in R A  patients treated w ith  m eth otrexate. The associa tion  b etw een  ch an ges in 
clin ical param eters and ch an ges in laboratory param eters w as generally  poor. T h ese  data 
im ply that the im provem ent in laboratory o u tco m es m ust be evaluated in con junctions  
with ch an ges in c lin ica l o u tco m es to co m p le te ly  a sse s  the response o f  R A  patients to anti­
rheum atic drug therapy.
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